HCL-GROUP
24.5.2022 19:18:07 CEST | Business Wire | Press release
Water security has never been more urgent. With the global population set to hit 8.5 billion by 2030, pressure is increasing on the world’s limited supply of freshwater. By 2030, the global demand for water will have exceeded sustainable supply by 40%. In addition to immediate and dire consequences to people’s health and food production, a lack of access to clean water can limit economic growth by up to one-third , as well as have adverse effects on natural biodiversity and social fabrics. Governments and businesses must bring freshwater to the forefront of their strategies, and innovation will play a key role in their success.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005757/en/
To drive the freshwater conservation and management agenda, leading global conglomerate HCL has partnered with UpLink, the open innovation platform of the World Economic Forum that connects highly-promising start-ups with the partners and funding they need to scale. Through a $15 million investment over five years, HCL will help accelerate the innovation agenda for water and create a first-of-its-kind innovation ecosystem for the global freshwater sector on UpLink, called the ‘Aquapreneur Innovation Initiative’.
This initiative will draw on HCL’s own regional experience of driving innovative projects in water conservation and brings global leaders and champions together, to foster multi-stakeholder collaboration. In building this ecosystem, water entrepreneurs will be able to thrive and influence freshwater ecosystems all over the world.
“Today, freshwater resources globally are extremely burdened and every fifth child on this planet faces water scarcity,” said Roshni Nadar Malhotra, CEO of HCL Group and Chairperson of HCL Technologies . “At HCL we want to make every effort to help resolve this global crisis. Our partnership with World Economic Forum’s UpLink platform is a step in this direction and our ecosystem approach can be truly transformative. Together we will not just encourage and scale innovations in this critical area, but also help build capacity amongst water-focused entrepreneurs - aquapreneurs - to execute on the innovative solutions. Through the Aquapreneur Innovation Initiative, we are re-committing to accelerate multi-stakeholder collaboration and innovation in the global freshwater conservation space.”
HCL’s new collaboration with UpLink will encompass building the freshwater innovation ecosystem including: running innovation challenges to source solutions from ‘aquapreneurs’ (water focused entrepreneurs), connecting these aquapreneurs to existing initiatives and water networks, unlocking funding opportunities to scale their ventures and raising awareness on the global agenda on the importance of freshwater.
Together, HCL & UpLink will also aim to help aquapreneurs build their skills and leadership capacity. Combined, these efforts will help drive and accelerate the innovation agenda for water and the sector’s mainstream ideas, approaches and solutions.
“The Aquapreneur Innovation Initiative comes at a critical time,” said Olivier Schwab, Managing Director, World Economic Forum. “With water scarcity enveloping regions around the world, we need to fast-track progress within the freshwater sector and build security for people and planet. HCL’s collaboration with UpLink will harness and drive forward the solutions of the world’s top innovators, connecting them to the initiatives and networks which can see them scale and drive transformational change for the world’s most fragile water systems.”
Innovation in freshwater management is also critical for water’s role in the transition to a green economy, as highlighted in the release of a new report in Davos today, A Freshwater Future: Without Blue, There Is No Green Economy .
UpLink was launched at the World Economic Forum Annual Meeting 2020 in collaboration with founding partners, Salesforce and Deloitte. The platform sources new innovations through a competition framework known as innovation challenges. UpLink has now run more than 30 challenges and identified over 260 entrepreneurs with innovative solutions for the world’s most pressing issues.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.
HCL Technologies, a group company, empowers global enterprises with technology for the next decade, today. As a leading global technology company, it takes pride in its diversity, social responsibility, sustainability and education initiatives. HCL Technologies is also a strategic partner of the World Economic Forum.
For further information, visit www.hcl.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005757/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
